| Similar Articles |
|---|
 |
Pharmaceutical Executive
September 1, 2011 |
The Power of PDP Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?   |
Bio-IT World
Dec 2005/Jan 2006
Salvatore Salamone |
Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises. |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
Pharmaceutical Executive
September 1, 2011 |
Filling Front and Center in the Fight against TB Dr. Mel Spigelman, President and CEO of the TB Alliance, discusses the organization's priorities in developing treatments for tuberculosis. |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
Pharmaceutical Executive
February 1, 2006
Joanna Breitstein |
Breath of Hope: TB in Africa For the first time in decades, the pharmaceutical industry has tuberculosis drugs in the pipeline. But it will take more than new pills to solve the problem. |
Pharmaceutical Executive
July 10, 2014
Fitzpatrick & Mohan |
Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance. |
Pharmaceutical Executive
February 1, 2012 |
Brazil Report: A Bold Player Blooms Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now. |
BusinessWeek
April 26, 2004
Kerry Capell |
Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money. |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive
May 1, 2006
Pasternak et al. |
Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity? |
HBS Working Knowledge
February 28, 2005
Cynthia Churchwell |
Funding R&D for Neglected Diseases Research on vaccines for diseases that primarily affect low-income countries remains minimal---the risks are too high for developers. The book Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases suggests a solution. |
The Motley Fool
June 26, 2008
Brian Lawler |
Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay. |
Chemistry World
August 15, 2012 |
The latent threat of tuberculosis Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease |
Smithsonian
November 2005 |
35 Who Made a Difference: Bill Gates The king of software takes on his biggest challenge yet: his foundation is reshaping the landscape of deadly and debilitating diseases in the developing world. |
BusinessWeek
July 25, 2005
Catherine Arnst |
O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge. |
Wired
July 24, 2007
Thomas Goetz |
The Ultimate Diagnostic Device (By the Way, You've Got Drug-Resistant TB!) The CDC's goal of a tuberculosis-free society grew short due to the development of drug-resistant strains. But new standards for detection are in the works. |
The Motley Fool
December 30, 2008
Brian Orelli |
A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus. |
HBS Working Knowledge
March 1, 2004
Martha Lagace |
Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends. |
Pharmaceutical Executive
November 1, 2014
Casey McDonald |
Advocacy Beat: Progress in Global Access to TB Drugs Treatment Action Group reaches a milestone in improving access to much-needed treatments for tuberculosis. |
American Family Physician
December 1, 2005 |
Tuberculosis: What You Should Know A patient hand-out on the disease, who is susceptible, its treatment and medication recommendation. |
